title: Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era.
abstract: Parvovirus B19 infection causes transient aplastic crisis in sickle cell disease (SCD) due to a temporary interruption in the red blood cell production. Toxicity from hydroxyurea includes anemia and reticulocytopenia, both of which also occur during a transient aplastic crisis event. Hydroxyurea inhibits proliferation of hematopoietic cells and may be immunosuppressive. We postulated that hydroxyurea could exacerbate parvovirus B19-induced aplastic crisis and inhibit the development of specific immune responses in children with SCD. We conducted a retrospective review of parvovirus B19 infection in 330 children with SCD. Altogether there were 120 known cases of aplastic crisis attributed to parvovirus B19 infection, and 12% of children were on hydroxyurea treatment during the episode. We evaluated hematological and immune responses. Children with HbSS or HbSβ(0)-thalassemia treated with hydroxyurea, when compared with untreated children, required fewer transfusions and had higher Hb concentration nadir during transient aplastic crisis. Duration of hospital stays was no different between hydroxyurea-treated and untreated groups. Children tested within a week following aplastic crisis were positive for parvovirus-specific IgG. Immune responses lasted for the duration of the observation period, up to 13 years after transient aplastic crisis, and there were no repeat aplastic crisis episodes. The frequencies of parvovirus-specific antibodies in all children with SCD increased with age, as expected due to the increased likelihood of a parvovirus exposure, and were comparable to frequencies reported for healthy children. Approximately one-third of children had a positive parvovirus B19-specific IgG test without a documented history of transient aplastic crisis, and 64% of them were treated with hydroxyurea. Hydroxyurea may reduce requirements for blood transfusions and may attenuate symptoms during transient aplastic crisis episodes caused by parvovirus B19 infections. Children with SCD, whether treated or untreated with hydroxyurea, generate sustained and protective parvovirus B19-specific immune responses.
authors.affiliation: Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA jane.hankins@stjude.org.
authors.forename: Jane S
authors.initials: JS
authors.lastname: Hankins
authors.affiliation: Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
authors.forename: Rhiannon R
authors.initials: RR
authors.lastname: Penkert
authors.affiliation: Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Lavoie
authors.affiliation: Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
authors.forename: Li
authors.initials: L
authors.lastname: Tang
authors.affiliation: Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
authors.forename: Yilun
authors.initials: Y
authors.lastname: Sun
authors.affiliation: Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA Department of Microbiology, Immunology and Biochemistry, University of Tennessee, Memphis, TN 38105, USA.
authors.forename: Julia L
authors.initials: JL
authors.lastname: Hurwitz
mesh_terms: D000293:Adolescent; D000755:Anemia, Sickle Cell / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D000986:Antisickling Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D017707:Erythrocyte Transfusion; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007223:Infant; D010322:Parvoviridae Infections / Q000150:complications*; D016732:Parvovirus B19, Human; D012189:Retrospective Studies
chemical_list: D000986:Antisickling Agents; D006918:Hydroxyurea
keywords: Sickle cell anemia; hydroxycarbamide; immune response